Tezspire meets Phase 3 endpoints in eosinophilic esophagitis

AstraZeneca and Amgen reported that tezepelumab (Tezspire) met both co-primary endpoints of histologic remission and reduced dysphagia, with results persisting through week 52 in the Phase III CROSSING trial for eosinophilic esophagitis. The study also showed improvements across key secondary endpoints compared with placebo, reinforcing the therapy’s potential in addressing a high-need autoimmune-like esophageal condition. Tezspire, a monoclonal antibody that blocks TSLP, is already approved for severe asthma and chronic rhinosinusitis with nasal polyps, and is being explored for a broader label. Analysts and press notes emphasize the durability of responses and the strategic opportunity to extend Tezspire into multiple epithelial-driven diseases, potentially broadening its commercial footprint. The data underscore Tezspire’s role as a platform asset with potential cross-label benefits across inflammatory diseases, including expansion into new indications beyond eosinophilic esophagitis. Regulatory and payer considerations are likely to focus on the real-world impact of histologic and symptomatic improvements and the consistency of safety with existing uses.